A series of key improvements being introduced in the biopharmaceutical industry by the Taizhou Medical High-tech Zone – also known as Gaogang district, located in Taizhou city, in East China's Jiangsu province – recently won recognition.
It was announced that the zone had been recognized as a quality improvement demonstration project in the Yangtze River Delta region.
The project is being led by the zone's market regulations bureau and after two years of efforts it is said to have achieved great results in promoting the high-quality development of the regional biopharma sector.
The program has helped the zone's biopharmaceutical industry to expand and it's now home to over 1,200 pharma enterprises, with it having registered over 2,100 leading pharmaceutical innovation achievements.
Moreover, the number of its biopharma groups listed on the sci-tech innovation board ranked top in Jiangsu province.
The construction of major carriers in the zone has been promoted, such as a medical and health industry innovation center that was co-built with the Peking University Health Science Center and the ICGEB-China Regional Research Center.
Overall, the project has promoted the zone's development of the biopharmaceutical industry. The area is now home to five provincial or municipal quality award enterprises and four provincial quality credit AA level or above enterprises.
What's more, it has led or participated in the formulation and revision of 18 national and industry standards.
An exterior view of the offices of two major innovation carriers in the Taizhou Medical High-tech Zone. [Photo/WeChat account: weigg6666]